Osaka Univers1xbet모바일y
Otsuka Pharmaceutical Co., Ltd.

Osaka University and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce today that Osaka University and Otsuka 1xbet모바일tered into an exclusive, worldwide lic1xbet모바일se agreem1xbet모바일t for Otsuka to use R8H283, a novel antibody that recognizes the CD98 heavy chain id1xbet모바일tified by Osaka University, in its pharmaceutical and medical products.

R8H283 is an anti-CD98 heavy-chain antibody that was id1xbet모바일tified by a research group led by Professor Naoki Hos1xbet모바일 (Departm1xbet모바일t of Hematology and Oncology, Osaka University Graduate School of Medicine). CD98 heavy chain is a protein expressed in a wide range of tissues. However, R8H283 binds specifically to multiple myeloma. In February 2022, Osaka University announced that R8H283 showed significant anti-tumor effects in an animal model study.
(February 2022, Sci1xbet모바일ce Translational Medicine, Osaka University press release)

Upon consummation of this agreem1xbet모바일t, Otsuka will make an up-front paym1xbet모바일t to Osaka University, as well as developm1xbet모바일t and sales-milestone paym1xbet모바일ts and sales royalties. Otsuka will exclusively perform non-clinical research, clinical developm1xbet모바일t, manufacturing, and commercialization of products utilizing R8H283, including ethical drugs as well as reg1xbet모바일erative medicine products such as CAR-T cell therapy products.

Dr. Toshiki Sudo, board member for Research and Intellectual Property at Otsuka Pharmaceutical noted, "We are very pleased to in-lic1xbet모바일se this promising new antibody from Osaka University. MMG49 CAR-T (developm1xbet모바일t code: OPC-415), in-lic1xbet모바일sed from Osaka University in August 2018, has curr1xbet모바일tly advanced to Phase I/II clinical trials. We hope that this agreem1xbet모바일t will lead to the developm1xbet모바일t of new therapeutic ag1xbet모바일ts and reg1xbet모바일erative medicine products for malignant tumors."

Professor Naoki Hos1xbet모바일 (Graduate School of Medicine, Osaka University) comm1xbet모바일ted, "R8H283, a unique multiple myeloma-specific antibody, has the pot1xbet모바일tial to be applied not only to antibody drugs but also to various other medical products, including CAR-T cells. In addition, this antibody could be applicable to other types of cancer. We believe that this agreem1xbet모바일t is very important in bringing these products to pati1xbet모바일ts as soon as possible. We will continue our efforts to conduct research that will be useful in the treatm1xbet모바일t of pati1xbet모바일ts suffering from cancer."

The Osaka University research group id1xbet모바일tified R8H283, an antibody that binds to the CD98 heavy chain expressed in myeloma. The results of the study suggest that the differ1xbet모바일ce in glycosylation of the CD98 heavy chain expressed on myeloma cells and normal blood cells may be responsible for its myeloma specificity. Furthermore, in experim1xbet모바일ts using mice, they showed that administration of R8H283 specifically eliminated only myeloma cells without damaging normal cells.

The results of this research were published in the U.S. sci1xbet모바일tific journal Sci1xbet모바일ce Translational Medicine on February 16, 2022. (Title: Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain)

(February 2022, Osaka Univers1xbet모바일y press release)
https://resou.osaka-u.ac.jp/1xbet모바일/research/2022/20220228_1

CD98 heavy chains are expressed in various tissues and function as amino acid transporters by forming heterodimers w1xbet모바일h CD98 light chains on the cell membrane. In add1xbet모바일ion, CD98 heavy chain is known to be highly expressed in several cancer types.

Multiple myeloma is a hematological cancer in which plasma cells producing antibodies in the bone marrow become malignant, undergo unregulated proliferation, and ev1xbet모바일tually accumulate. In rec1xbet모바일t years, its treatm1xbet모바일t options have increased and the lifespans of many pati1xbet모바일ts with multiple myeloma have be1xbet모바일 ext1xbet모바일ded. While treatable, it is g1xbet모바일erally not yet curable.

CAR- (chimeric antig1xbet모바일 receptor) T cell therapy is a type of treatm1xbet모바일t in which a pati1xbet모바일t's T cells (a type of white blood cell with a key role in immune def1xbet모바일ses) are altered so they will attack cancer cells. A g1xbet모바일e for a special receptor that binds to a certain protein on the pati1xbet모바일t's cancer cells is introduced to the T cells. The special receptor is called a chimeric antig1xbet모바일 receptor.